Polyclonal Antibody to Phosphoinositide-3-Kinase Class-2-Beta Polypeptide (PIK3C2b)
Code | Size | Price |
---|
PAJ826Ra01-20ul | 20ul | £92.00 |
Quantity:
PAJ826Ra01-100ul | 100ul | £173.00 |
Quantity:
PAJ826Ra01-200ul | 200ul | £234.00 |
Quantity:
PAJ826Ra01-1ml | 1ml | £539.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Rat
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunocytochemistry (ICC)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
C2-PI3K; PI3K-C2beta; Phosphoinositide 3-kinase-C2-beta
Buffer Formulation:
PBS, pH7.4, containing 0.02% NaN3, 50% glycerol.
Item Name:
Phosphoinositide-3-Kinase Class-2-Beta Polypeptide
Source:
Polyclonal antibody preparation
Usage:
Western blotting: 0.01-2ug/mL;<br/>Immunohistochemistry: 5-20ug/mL;<br/>Immunocytochemistry: 5-20ug/mL;<br/>Optimal working dilutions must be determined by end user.
References
https://sciencedirect.53yu.com/science/article/pii/S0041008X22003180; https://onlinelibrarywiley.53yu.com/doi/abs/10.1111/jpi.12869;
Related Products
Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Recombinant Phosphoinositide-3-Kinase Class-2-Beta Polypeptide (PIK3C2b) | RPJ826Ra01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||